Jeffrey R Liddell

List of Publications by Year
in descending order

33 papers	2,027 citations	279798 23 h-index	395702 33 g-index
37 all docs	37 docs citations	37 times ranked	2772 citing authors

#	Article	IF	Citations
1	Targeting Nrf2 to Suppress Ferroptosis and Mitochondrial Dysfunction in Neurodegeneration. Frontiers in Neuroscience, 2018, 12, 466.	2.8	287
2	Molecular mechanisms of cell death in neurological diseases. Cell Death and Differentiation, 2021, 28, 2029-2044.	11.2	268
3	Oral Treatment with CuII(atsm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. Journal of Neuroscience, 2014, 34, 8021-8031.	3.6	161
4	Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration?. Antioxidants, 2017, 6, 65.	5.1	126
5	Endogenous TDP-43 localized to stress granules can subsequently form protein aggregates. Neurochemistry International, 2012, 60, 415-424.	3.8	125
6	C-Jun N-terminal kinase controls TDP-43 accumulation in stress granules induced by oxidative stress. Molecular Neurodegeneration, 2011, 6, 57.	10.8	103
7	An impaired mitochondrial electron transport chain increases retention of the hypoxia imaging agent diacetylbis(4-methylthiosemicarbazonato)copper ^{II}. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 47-52.	7.1	101
8	Therapeutic effects of Cu^{II}(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 586-590.	1.7	82
9	TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway. Human Molecular Genetics, 2017, 26, 1732-1746.	2.9	62
10	Kinase Inhibitor Screening Identifies Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 as Potential Modulators of TDP-43 Cytosolic Accumulation during Cell Stress. PLoS ONE, 2013, 8, e67433.	2.5	50
11	Phosphorylation of hnRNP K by cyclin-dependent kinase 2 controls cytosolic accumulation of TDP-43. Human Molecular Genetics, 2015, 24, 1655-1669.	2.9	48
12	Nexus between mitochondrial function, iron, copper and glutathione in Parkinson's disease. Neurochemistry International, 2018, 117, 126-138.	3.8	46
13	Inhibition of TDP-43 Accumulation by Bis(thiosemicarbazonato)-Copper Complexes. PLoS ONE, 2012, 7, e42277.	2.5	44
14	The challenges of using a copper fluorescent sensor (CS1) to track intracellular distributions of copper in neuronal and glial cells. Chemical Science, 2012, 3, 2748.	7.4	43
15	Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain. Human Molecular Genetics, 2014, 23, 4051-4063.	2.9	41
16	Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by rapid online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry. Metallomics, 2013, 5, 1656.	2.4	39
17	Neuroprotective Copper Bis(thiosemicarbazonato) Complexes Promote Neurite Elongation. PLoS ONE, 2014, 9, e90070.	2.5	39
18	Circumventing the Crabtree Effect: A method to induce lactate consumption and increase oxidative phosphorylation in cell culture. International Journal of Biochemistry and Cell Biology, 2016, 79, 128-138.	2.8	38

#	Article	IF	Citations
19	Pyrrolidine dithiocarbamate activates the Nrf2 pathway in astrocytes. Journal of Neuroinflammation, 2016, 13, 49.	7.2	38
20	Deregulation of subcellular biometal homeostasis through loss of the metal transporter, Zip7, in a childhood neurodegenerative disorder. Acta Neuropathologica Communications, 2014, 2, 25.	5.2	37
21	Astrocytes retain their antioxidant capacity into advanced old age. Glia, 2010, 58, 1500-1509.	4.9	34
22	ZnII(atsm) is protective in amyotrophic lateral sclerosis model mice via a copper delivery mechanism. Neurobiology of Disease, 2015, 81, 20-24.	4.4	28
23	Neuron-astrocyte transmitophagy is altered in Alzheimer's disease. Neurobiology of Disease, 2022, 170, 105753.	4.4	27
24	Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease. Free Radical Biology and Medicine, 2013, 60, 147-156.	2.9	26
25	CuII(atsm) Attenuates Neuroinflammation. Frontiers in Neuroscience, 2018, 12, 668.	2.8	26
26	A versatile quantitative microdroplet elemental imaging method optimised for integration in biochemical workflows for low-volume samples. Analytical and Bioanalytical Chemistry, 2019, 411, 603-616.	3.7	19
27	Subcellular localization of a fluorescent derivative of CuII(atsm) offers insight into the neuroprotective action of CuII(atsm). Metallomics, 2011, 3, 1280.	2.4	17
28	Copper-ATSM as a Treatment for ALS: Support from Mutant SOD1 Models and Beyond. Life, 2020, 10, 271.	2.4	17
29	Targeting mitochondrial metal dyshomeostasis for the treatment of neurodegeneration. Neurodegenerative Disease Management, 2015, 5, 345-364.	2.2	12
30	Copper modulates the large dense core vesicle secretory pathway in PC12 cells. Metallomics, 2013, 5, 700.	2.4	10
31	Adamantyl- and other polycyclic cage-based conjugates of desferrioxamine B (DFOB) for treating iron-mediated toxicity in cell models of Parkinsonâ€™s disease. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1698-1704.	2.2	10
32	Regular Physical Exercise Modulates Iron Homeostasis in the 5xFAD Mouse Model of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 8715.	4.1	10
33	Biometal Dyshomeostasis in Olfactory Mucosa of Alzheimerâ€™s Disease Patients. International Journal of Molecular Sciences, 2022, 23, 4123.	4.1	3